4.8 Article

Progressive Tumor Formation in Mice with Conditional Deletion of TGF-β Signaling in Head and Neck Epithelia Is Associated with Activation of the PI3K/Akt Pathway

期刊

CANCER RESEARCH
卷 69, 期 14, 页码 5918-5926

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-4623

关键词

-

类别

资金

  1. Intramural Research Program, National Institute of Dental and Craniofacial Research, NIH

向作者/读者索取更多资源

The precise role of transforming growth factor (TGF)-beta signaling in head and neck squamous cell carcinoma (SCC) is not yet fully understood. Here, we report generation of an inducible head- and neck-specific knockout mouse model by crossing TGF-beta receptor 1 (Tgfbr1) floxed mice with K14-CreER(lam) mice. By applying tamoxifen to oral cavity of the mouse to induce Cre expression, we were able to conditionally delete Tgfbr1 in the mouse head and neck epithelia. on tumor induction with 7,12-dimethylbenz(a)anthracene (DMBA), 45% of Tgfbr1 conditional knockout (cKO) mice (n = 42) developed SCCs in the head and neck area starting from 16 weeks after treatment. However, no tumors were observed in the control littermates. A molecular analysis revealed an enhanced proliferation and loss of apoptosis in the basal layer of the head and neck epithelia of Tgfbr1 cKO mice 4 weeks after tamoxifen and DMBA treatment. The most notable finding of our study is that the phosphoinositide 3-kinase (PI3K)/Akt pathway was activated in SCCs that developed in the Tgfbr1 cKO mice on inactivation of TGF-beta signaling through Smad2/3 and DMBA treatment. These observations suggest that activation of Smad-independent pathways may contribute cooperatively with inactivation of Smad-dependent pathways to promote head and neck carcinogenesis in these mice. Our results revealed the critical role of the TGF-beta signaling pathway and its crosstalk with the PI3K/Akt pathway in suppressing head and neck carcinogenesis. [Cancer Res 2009;69(14):5918-26]

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Structural/functional studies of Trio provide insights into its configuration and show that conserved linker elements enhance its activity for Rac1

Sumit J. Bandekar, Chun-Liang Chen, Sandeep K. Ravala, Jennifer N. Cash, Larisa V. Avramova, Mariya V. Zhalnina, J. Silvio Gutkind, Sheng Li, John J. G. Tesmer

Summary: The Trio scaffold contains two GEF modules selective for Rac and RhoA GTPases, with the C-terminal region enhancing Rac1 GEF activity. Characterization of accessory Trio domains may provide alternate routes for developing therapeutics to inhibit Trio activity in human cancer.

JOURNAL OF BIOLOGICAL CHEMISTRY (2022)

Article Multidisciplinary Sciences

Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy

Dina Hingorani, Michael M. Allevato, Maria F. Camargo, Jacqueline Lesperance, Maryam A. Quraishi, Joseph Aguilera, Ida Franiak-Pietryga, Daniel J. Scanderbeg, Zhiyong Wang, Alfredo A. Molinolo, Diego Alvarado, Andrew B. Sharabi, Jack D. Bui, Ezra E. W. Cohen, Stephen R. Adams, J. Silvio Gutkind, Sunil J. Advani

Summary: The authors show that the combination of monomethyl auristatin and radiotherapy can promote anti-tumor immune responses and improve the response to checkpoint inhibitors in cancer therapy. This trimodal precision cytotoxic chemo-radio-immunotherapy paradigm has the potential to improve tumor control and patient outcomes.

NATURE COMMUNICATIONS (2022)

Review Oncology

HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer

Robert Saddawi-Konefka, Shiruyeh Schokrpur, Asona J. Lui, J. Silvio Gutkind

Summary: Research has shown that abnormalities in the ErbB signaling pathways play a crucial role in oncogenesis, and efforts to target these aberrations offer great potential in treating various types of cancer. While the focus has primarily been on the EGFR pathway, recent studies have identified significant dysregulation in the HER2 and HER3 signaling pathways in head and neck cancer. This review highlights clinical efforts to target these receptors and their aberrant signaling, including the use of small molecule inhibitors and blocking antibodies, in the treatment of head and neck squamous cell carcinomas and other malignancies.

CANCER JOURNAL (2022)

Article Oncology

Challenges and Emerging Opportunities for Targeting mTOR in Cancer

Kris C. Wood, J. Silvio Gutkind

CANCER RESEARCH (2022)

Article Oncology

A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck

Cherie-Ann O. Nathan, D. Neil Hayes, Theodore Karrison, Olivier Harismendy, Jose M. Flores, Tara Moore-Medlin, Everett E. Vokes, J. Silvio Gutkind, Prakash Neupane, Glenn Mills, Zoukaa Sargi, Tanguy Seiwert, Juneko Grilley-Olson, Terry Day, Maura Gillison, James L. Wade, Lawrence Feldman, Gautam Jha, Mark Kozloff, Miriam O'Leary, Francis P. Worden, Ezra E. W. Cohen

Summary: This study aimed to investigate whether adjuvant everolimus, an mTOR inhibitor, improves progression-free survival in advanced-stage HNSCC patients and to explore outcomes related to disease control-associated biological factors. The results suggest that p16-negative and TP53-mutated patients may benefit from adjuvant treatment with everolimus.

CLINICAL CANCER RESEARCH (2022)

Review Health Care Sciences & Services

Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine

Toshinori Ando, Kento Okamoto, Tomoaki Shintani, Souichi Yanamoto, Mutsumi Miyauchi, J. Silvio Gutkind, Mikihito Kajiya

Summary: Genetic alterations and dysregulation of signaling pathways are crucial for the development of cancer. Precision medicine allows for the selection of appropriate treatments based on genetic variations. Various genetic alterations in HNSCC disrupt the Hippo pathway and lead to hyperactivation of YAP/TAZ.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Article Biochemistry & Molecular Biology

Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry

Nadia Arang, Simone Lubrano, Damiano Cosimo Rigiracciolo, Daniela Nachmanson, Scott M. Lippman, Prashant Mali, Olivier Harismendy, J. Silvio Gutkind

Summary: G proteins and G protein-coupled receptors activate signal transduction pathways that promote cell growth and survival. This study found that G alpha q promotes PI3K/AKT signaling pathway activation, leading to resistance to FAK inhibition. These findings establish a novel link between G alpha q-driven signaling and the stimulation of PI3K, demonstrating the aberrant activation of signaling networks underlying the growth and survival of UM and other G alpha q-driven malignancies.

JOURNAL OF BIOLOGICAL CHEMISTRY (2023)

Article Oncology

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

Alison E. Smith, Stacia Chan, Zhiyong Wang, Asako Mccloskey, Quinn Reilly, Jayden Z. Wang, Hetika Vora Patel, Keiichi Koshizuka, Harris S. Soifer, Linda Kessler, Ashley Dayoub, Victoria Villaflor, Douglas R. Adkins, Justine Y. Bruce, Alan L. Ho, Cesar A. Perez, Glenn J. Hanna, Amaya Gasco Hernandez, Andrew Saunders, Stephen Dale, J. Silvio Gutkind, Francis Burrows, Shivani Malik

Summary: The outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) are poor, and there are limited treatment options for those who progress on standard-of-care immunotherapy. Researchers have developed a combination therapy targeting the key drivers of HNSCC, PI3K-mTOR and HRAS, using the inhibitors tipifarnib and alpelisib. This combination therapy has shown promise in preclinical studies and early clinical trials, with potential to benefit over 45% of patients with recurrent/metastatic HNSCC. Additionally, tipifarnib may enhance the effectiveness of other targeted therapies by preventing adaptive resistance.

CANCER RESEARCH (2023)

Article Oncology

Mutated HRAS Activates YAP1-AXL Signaling to Drive Metastasis of Head and Neck Cancer

Sankar Jagadeeshan, Manu Prasad, Mai Badarni, Talal Ben-Lulu, Vijayasteltar Belsamma Liju, Sooraj Mathukkada, Claire Saunders, Avital Beeri Shnerb, Jonathan Zorea, Ksenia M. Yegodayev, Monica Wainer, Liza Vtorov, Irit Allon, Ofir Cohen, Gro Gausdal, Dinorah Friedmann-Morvinski, Sok Ching Cheong, Alan L. Ho, Ari J. Rosenberg, Linda Kessler, Francis Burrows, Dexin Kong, Jennifer R. Grandis, J. Silvio Gutkind, Moshe Elkabets

Summary: The presence of mutated HRAS in head and neck cancer patients is associated with poor prognosis and high metastasis rate. Mutated HRAS promotes cancer cell invasion and metastasis by suppressing the Hippo pathway and promoting AXL expression. The use of tipifarnib, a farnesyltransferase inhibitor, can activate the Hippo pathway, suppress metastasis, and regulate angiogenesis in HNC.

CANCER RESEARCH (2023)

Article Biotechnology & Applied Microbiology

CTLA-4 blockade induces tumor pyroptosis via CD8+T cells in head and neck squamous cell carcinoma

Shuo Wang, Zhi-Zhong Wu, Su-Wen Zhu, Shu-Cheng Wan, Meng-Jie Zhang, Bo-Xin Zhang, Qi-Chao Yang, Yao Xiao, Hao Li, Liang Mao, Zhi-Yong Wang, J. Silvio Gutkind, Zhi-Jun Sun

Summary: Immune checkpoint blockade (ICB) treatment is effective in oncology, but has limitations including low response rates and a lack of efficacy predictors. Gasdermin protein expression is associated with a favorable tumor immune microenvironment and prognosis in head and neck squamous cell carcinoma. CTLA-4 blockade treatment induces gasdermin-mediated pyroptosis of tumor cells, with gasdermin expression correlating with treatment effectiveness. CTLA-4 blockade activates CD8+ T cells and increases levels of IFN-g and TNF-a cytokines, triggering tumor cell pyroptosis and release of inflammatory substances and chemokines.

MOLECULAR THERAPY (2023)

Article Immunology

The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure

Victoria H. Wu, Bryan S. Yung, Farhoud Faraji, Robert Saddawi-Konefka, Zhiyong Wang, Alexander T. Wenzel, Miranda J. Song, Meghana S. Pagadala, Lauren M. Clubb, Joshua Chiou, Sanju Sinha, Marin Matic, Francesco Raimondi, Thomas S. Hoang, Rebecca Berdeaux, Dario A. A. Vignali, Ramiro Iglesias-Bartolome, Hannah Carter, Eytan Ruppin, Jill P. Mesirov, J. Silvio Gutkind

Summary: The authors used computational screening and chemogenetic analysis of transgenic mice to show that G alpha(s)-coupled G-protein-coupled receptors (GPCRs) on exhausted CD8(+) T cells play a role in suppressing effector functions and inhibiting the protective effects of immune checkpoint immunotherapy. They found an enrichment of G alpha(s)-coupled GPCRs on exhausted CD8(+) T cells and identified several specific receptors that promote T cell dysfunction. By activating the G alpha(s) signaling axis, they demonstrated that CD8(+) T cell dysfunction and immunotherapy failure can be promoted. These findings suggest that G alpha(s)-GPCRs could be targeted to enhance the response to immune checkpoint blockade immunotherapies.

NATURE IMMUNOLOGY (2023)

Article Biochemistry & Molecular Biology

Catalytic site mutations confer multiple states of G protein activation

Natalie Hewitt, Ning Ma, Nadia Arang, Sarah A. Martin, Ajit Prakash, Jeffrey F. DiBerto, Kevin M. Knight, Soumadwip Ghosh, Reid H. J. Olsen, Bryan L. Roth, J. Silvio Gutkind, Nagarajan Vaidehi, Sharon L. Campbell, Henrik G. Dohlman

Summary: Heterotrimeric guanine nucleotide-binding proteins (G proteins) act as molecular switches for cellular growth and metabolism. Mutations in the glutamine residue critical for GTP hydrolysis in the G protein alpha subunit are common in uveal melanoma. Our study reveals that these mutations have functional diversity and contribute to G protein functions beyond GTP hydrolysis.

SCIENCE SIGNALING (2023)

Article Multidisciplinary Sciences

Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response

Meghana Pagadala, Timothy J. Sears, Victoria H. Wu, Eva Perez-Guijarro, Hyo Kim, Andrea Castro, James V. Talwar, Cristian Gonzalez-Colin, Steven Cao, Benjamin J. Schmiedel, Shervin Goudarzi, Divya Kirani, Jessica Au, Tongwu Zhang, Teresa Landi, Rany M. Salem, Gerald P. Morris, Olivier Harismendy, Sandip Pravin Patel, Ludmil B. Alexandrov, Jill P. Mesirov, Maurizio Zanetti, Chi-Ping Day, Chun Chieh Fan, Wesley K. Thompson, Glenn Merlino, J. Silvio Gutkind, Pandurangan Vijayanand, Hannah Carter

Summary: Understanding how host genetics affects the tumor immune microenvironment (TIME) is essential for personalized cancer screening and treatment strategies. A study analyzed the eQTLs affecting TIME and found that they are enriched in areas of active transcription and associated with gene expression in specific immune cell subsets. Polygenic score models built with TIME eQTLs can stratify cancer risk, survival, and immune checkpoint blockade (ICB) response. Inhibiting the CTSS gene, which is implicated by the polygenic models, slows tumor growth and extends survival, suggesting the potential of integrating genetic factors and TIME characteristics for immunotherapy targets.

NATURE COMMUNICATIONS (2023)

Article Oncology

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors

Ana Ruiz-Saenz, Chloe E. Atreya, Changjun Wang, Bo Pan, Courtney A. Dreyer, Diede Brunen, Anirudh Prahallad, Denise P. Munoz, Dana J. Ramms, Valeria Burghi, Danislav S. Spassov, Eleanor Fewings, Yeonjoo C. Hwang, Cynthia Cowdrey, Christina Moelders, Cecilia Schwarzer, Denise M. Wolf, Byron Hann, Scott R. VandenBerg, Kevan Shokat, Mark M. Moasser, Rene Bernards, J. Silvio Gutkind, Laura J. van 't Veer, Jean-Philippe Coppe

Summary: Coppe and colleagues discover a resistance mechanism in BRAF(V600E) colorectal cancers that can be overcome with COX2 inhibitors. SRC kinases play a role in resistance to BRAF/EGFR-targeted therapy and can be effectively targeted in combination with BRAF and EGFR. Compensatory activation of SRC kinases is mediated by an autocrine prostaglandin E-2 loop, which can be blocked with COX2 inhibitors. Co-targeting COX2, BRAF, and EGFR promotes long-lasting suppression of tumor growth in patient-derived tumor xenograft models.

NATURE CANCER (2023)

Article Biochemistry & Molecular Biology

Gαs is dispensable for (3-arrestin coupling but dictates GRK selectivity and is predominant for gene expression regulation by (32-adrenergic receptor

Valeria Burghi, Justine S. Paradis, Adam Officer, Sendi Rafael Adame-Garcia, Xingyu Wu, Edda S. F. Matthees, Benjamin Barsi-Rhyne, Dana J. Ramms, Lauren Clubb, Monica Acosta, Pablo Tamayo, Michel Bouvier, Asuka Inoue, Mark von Zastrow, Carsten Hoffmann, J. Silvio Gutkind

Summary: This study focuses on the role of beta-arrestins in G protein-coupled receptor (GPCR) signaling. It is found that while G proteins are essential for GPCR signaling, beta-arrestins play a more prominent role in signal compartmentalization and modulation of gene expression.

JOURNAL OF BIOLOGICAL CHEMISTRY (2023)

暂无数据